Publication of Annual Report and notice of AGM

Released : 19.10.2017

RNS Number : 1267U
Allergy Therapeutics PLC
19 October 2017
 

19 October 2017

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

 

ANNUAL FINANCIAL REPORT 2017 AND NOTICE OF 2017 ANNUAL GENERAL MEETING

 

 

Allergy Therapeutics Plc has today published the following documents:

 

·     Annual Report for the year ended 30 June 2017 ("Annual Report"); and

 

·     Notice of 2017 Annual General Meeting ("Notice of Meeting");

 

Each of these documents is available electronically on the Company's website at www.allergytherapeutics.com 

 

A hard copy of the Annual Report and Notice of Meeting is anticipated to be posted to shareholders on 19 October 2017.

 

 

- ENDS -

 

 

 

 

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / Ivar Milligan / Philippa Gardner

allergytherapeutics@consilium-comms.com

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBUBDGDBBBGRC